{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:29:12Z","timestamp":1788856152494,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12010-026-05619-8","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:27:28Z","timestamp":1773394048000},"page":"4115-4131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PKM2 Deficiency Results in Reduced Proliferation of Nasopharyngeal Carcinoma Cells by Deactivation of Nrf2-HO-1-GSH Signaling"],"prefix":"10.1007","volume":"198","author":[{"given":"Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"5619_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P., Chan, A. T. C., Le, Q. T., Blanchard, P., Sun, Y., & Ma, J. (2019). Nasopharyngeal carcinoma. Lancet (London, England), 394, 64\u201380.","journal-title":"Lancet (London, England)"},{"key":"5619_CR2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0270","volume":"372","author":"SW Tsao","year":"2017","unstructured":"Tsao, S. W., Tsang, C. M., & Lo, K. W. (2017). Epstein-Barr virus infection and nasopharyngeal carcinoma. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 372, Article 20160270.","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"5619_CR3","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez, C., Rodrigo, J. P., Rinaldo, A., Langendijk, J. A., Shaha, A. R., & Ferlito, A. (2010). Current treatment options for recurrent nasopharyngeal cancer. European archives of otorhinolaryngol, 267, 1811\u20131824.","DOI":"10.1007\/s00405-010-1385-x"},{"key":"5619_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt, S. Y., & Vander Heiden, M. G. (2011). Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annual Review of Cell and Developmental Biology, 27, 441\u2013464.","journal-title":"Annual Review of Cell and Developmental Biology"},{"key":"5619_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.15252\/embr.201643300","volume":"17","author":"TL Dayton","year":"2016","unstructured":"Dayton, T. L., Jacks, T., & Vander Heiden, M. G. (2016). PKM2, cancer metabolism, and the road ahead. EMBO Reports, 17, 1721\u20131730.","journal-title":"EMBO Reports"},{"key":"5619_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.biopha.2014.12.010","volume":"69","author":"T Dong","year":"2015","unstructured":"Dong, T., Yan, Y., Chai, H., Chen, S., Xiong, X., Sun, D., Yu, Y., Deng, L., & Cheng, F. (2015). Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1\u03b1 and Bcl-xL in culture. Biomedicine & Pharmacotherapy, 69, 277\u2013284.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"5619_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2014.12.005","volume":"21","author":"EM Palsson-McDermott","year":"2015","unstructured":"Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G., Jiang, J. K., Israelsen, W. J., Keane, J., Thomas, C., Clish, C., Vander Heiden, M., Xavier, R. J., & O\u2019Neill, L. A. (2015). Pyruvate kinase M2 regulates Hif-1\u03b1 activity and IL-1\u03b2 induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metabolism, 21, 65\u201380.","journal-title":"Cell Metabolism"},{"key":"5619_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s13402-018-0383-7","volume":"41","author":"G van Niekerk","year":"2018","unstructured":"van Niekerk, G., & Engelbrecht, A. M. (2018). Role of PKM2 in directing the metabolic fate of glucose in cancer: A potential therapeutic target. Cellular Oncology, 41, 343\u2013351.","journal-title":"Cellular Oncology"},{"key":"5619_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/abbs\/gmaa121","volume":"52","author":"Q Zhou","year":"2020","unstructured":"Zhou, Q., Tang, M., He, L., & Chen, S. (2020). PKM2: A crucial neuroprotective target against oxidative stress. Acta Biochimica Et Biophysica Sinica, 52, 1432\u20131434.","journal-title":"Acta Biochimica Et Biophysica Sinica"},{"key":"5619_CR10","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1126\/science.1211485","volume":"334","author":"D Anastasiou","year":"2011","unstructured":"Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., & Auld, D. S. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science, 334, 1278\u20131283.","journal-title":"Science"},{"key":"5619_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14788-x","volume":"11","author":"Y Wei","year":"2020","unstructured":"Wei, Y., Lu, M., Mei, M., Wang, H., Han, Z., Chen, M., Yao, H., Song, N., Ding, X., Ding, J., Xiao, M., & Hu, G. (2020). Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nature Communications, 11, Article 941.","journal-title":"Nature Communications"},{"key":"5619_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.molcel.2014.02.015","volume":"53","author":"KE Keller","year":"2014","unstructured":"Keller, K. E., Doctor, Z. M., Dwyer, Z. W., & Lee, Y.-S. (2014). SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Molecular Cell, 53, 700\u2013709.","journal-title":"Molecular Cell"},{"key":"5619_CR13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2749","volume":"6","author":"W-R Liu","year":"2014","unstructured":"Liu, W.-R., Tian, M.-X., Yang, L.-X., Lin, Y.-L., Jin, L., Ding, Z.-B., Shen, Y.-H., Peng, Y.-F., Gao, D.-M., & Zhou, J. (2014). PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 6, Article 846.","journal-title":"Oncotarget"},{"key":"5619_CR14","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1073\/pnas.1014769108","volume":"108","author":"Q Sun","year":"2011","unstructured":"Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., & Chen, R. (2011). Mammalian target of Rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proceedings of the National Academy of Sciences, 108, 4129\u20134134.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"5619_CR15","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1038\/onc.2015.397","volume":"35","author":"Y Yang","year":"2016","unstructured":"Yang, Y., Cheng, T., Huang, S., Su, C., Yang, P., Lee, J., Chen, C., Hsiao, M., Hua, K., & Kuo, M. (2016). Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90\u2013EGFR association. Oncogene, 35, 3387\u20133398.","journal-title":"Oncogene"},{"key":"5619_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF00193498","volume":"424","author":"U Brinck","year":"1994","unstructured":"Brinck, U., Fischer, G., Eigenbrodt, E., Oehmke, M., & Mazurek, S. (1994). L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Archiv, 424, 177\u2013185.","journal-title":"Virchows Archiv"},{"key":"5619_CR17","first-page":"91","volume":"3","author":"E Eigenbrodt","year":"1992","unstructured":"Eigenbrodt, E., Reinacher, M., Scheefers-Borchel, U., Scheefers, H., & Friis, R. (1992). Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Critical Reviews in Oncogenesis, 3, 91\u2013115.","journal-title":"Critical Reviews in Oncogenesis"},{"key":"5619_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/pmic.200300653","volume":"4","author":"SJ Ding","year":"2004","unstructured":"Ding, S. J., Li, Y., Shao, X. X., Zhou, H., Zeng, R., Tang, Z. Y., & Xia, Q. C. (2004). Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97\u2010L, with different metastasis potentials. Proteomics, 4, 982\u2013994.","journal-title":"Proteomics"},{"key":"5619_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452, 230\u2013233.","journal-title":"Nature"},{"key":"5619_CR20","doi-asserted-by":"crossref","unstructured":"Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005). Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in cancer biology, 15, 300-308.","DOI":"10.1016\/j.semcancer.2005.04.009"},{"key":"5619_CR21","first-page":"311","volume":"22","author":"J Schneider","year":"2002","unstructured":"Schneider, J., Neu, K., Grimm, H., Velcovsky, H.-G., Weisse, G., & Eigenbrodt, E. (2002). Tumor M2-pyruvate kinase in lung cancer patients: Immunohistochemical detection and disease monitoring. Anticancer Research, 22, 311\u2013318.","journal-title":"Anticancer Research"},{"key":"5619_CR22","first-page":"83","volume":"28","author":"A Ahmed","year":"2007","unstructured":"Ahmed, A., Dew, T., Lawton, F., Papadopoulos, A., Devaja, O., Raju, K., & Sherwood, R. (2007). M2-PK as a novel marker in ovarian cancer. A prospective cohort study. European Journal of Gynaecological Oncology, 28, 83\u201388.","journal-title":"European Journal of Gynaecological Oncology"},{"key":"5619_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2354.2006.00753.x","volume":"16","author":"R Weinberger","year":"2007","unstructured":"Weinberger, R., Appel, B., Stein, A., Metz, Y., Neheman, A., & Barak, M. (2007). The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. European Journal of Cancer Care, 16, 333\u2013337.","journal-title":"European Journal of Cancer Care"},{"key":"5619_CR24","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/ibd.20214","volume":"13","author":"G Chung-Faye","year":"2007","unstructured":"Chung-Faye, G., Hayee, B. H., Maestranzi, S., Donaldson, N., Forgacs, I., & Sherwood, R. (2007). Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation. Inflammatory Bowel Diseases, 13, 1374\u20131378.","journal-title":"Inflammatory Bowel Diseases"},{"key":"5619_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020427","volume":"11","author":"J Xu","year":"2022","unstructured":"Xu, J., Su, X., Burley, S. K., & Zheng, X. S. (2022). Nuclear SOD1 in growth control, oxidative stress response, amyotrophic lateral sclerosis, and cancer. Antioxidants, 11, Article 427.","journal-title":"Antioxidants"},{"key":"5619_CR26","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wu, B., Zhang, J., & Zhang, W. (2022). Lupeol triggers oxidative stress, ferroptosis, apoptosis and restrains inflammation in nasopharyngeal carcinoma via AMPK\/NF-\u03baB pathway. Immunopharmacology and Immunotoxicology, 44, 1\u201313.","DOI":"10.1080\/08923973.2022.2072328"},{"key":"5619_CR27","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.biopha.2016.10.108","volume":"84","author":"F Fan","year":"2016","unstructured":"Fan, F., Wu, H., Liu, Z., Hou, X., Chen, W., Wang, A., & Lu, Y. (2016). Nuclear PKM2 expression, an independent risk factor for ER after curative resection of hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 84, 1858\u20131864.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"5619_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1194-z","volume":"38","author":"J Feng","year":"2019","unstructured":"Feng, J., Wu, L., Ji, J., Chen, K., Yu, Q., Zhang, J., Chen, J., Mao, Y., Wang, F., Dai, W., Xu, L., Wu, J., & Guo, C. (2019). PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. Journal of experimental & clinical cancer research\u202f: CR, 38, Article 204.","journal-title":"Journal of experimental & clinical cancer research : CR"},{"key":"5619_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115036","volume":"9","author":"CC Wong","year":"2014","unstructured":"Wong, C. C., Au, S. L., Tse, A. P., Xu, I. M., Lai, R. K., Chiu, D. K., Wei, L. L., Fan, D. N., Tsang, F. H., Lo, R. C., Wong, C. M., & Ng, I. O. (2014). Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. PloS one, 9, Article e115036.","journal-title":"PloS one"},{"key":"5619_CR30","volume":"8","author":"A Paunkov","year":"2019","unstructured":"Paunkov, A., Chartoumpekis, D. V., Ziros, P. G., & Sykiotis, G. P. (2019). A bibliometric review of the Keap1\/Nrf2 pathway and its related antioxidant compounds. Antioxidants (Basel, Switzerland), 8, Article 353.","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"5619_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54065-6","volume":"9","author":"MM Silva","year":"2019","unstructured":"Silva, M. M., Rocha, C. R. R., Kinker, G. S., Pelegrini, A. L., & Menck, C. F. M. (2019). The balance between NRF2\/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Scientific Reports, 9, Article 17639.","journal-title":"Scientific Reports"},{"key":"5619_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/1759-7714.13252","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Zhang, J., Li, M., Kong, L., & Yu, J. (2020). The expression of p-p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance. Thoracic Cancer, 11, 130\u2013139.","journal-title":"Thoracic Cancer"},{"key":"5619_CR33","first-page":"678","volume":"32","author":"XK Ma","year":"2018","unstructured":"Ma, X. K., & Liu, J. S. (2018). [Expression patterns and prognostic values of Nrf2 and Keap1 in nasopharyngeal carcinoma]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery, 32, 678\u2013682.","journal-title":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery"},{"key":"5619_CR34","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.2147\/OTT.S260169","volume":"13","author":"J Zhou","year":"2020","unstructured":"Zhou, J., Ding, J., Ma, X., Zhang, M., Huo, Z., Yao, Y., Li, D., & Wang, Z. (2020). The NRF2\/KEAP1 pathway modulates nasopharyngeal carcinoma cell radiosensitivity via ROS elimination. OncoTargets and Therapy, 13, 9113\u20139122.","journal-title":"OncoTargets and Therapy"},{"key":"5619_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal, R., & Gupta, S. (2012). Epigenetic modifications in cancer. Clinical Genetics, 81, 303\u2013311.","journal-title":"Clinical Genetics"},{"key":"5619_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2005.07.034","volume":"42","author":"R Bianco","year":"2006","unstructured":"Bianco, R., Melisi, D., Ciardiello, F., & Tortora, G. (2006). Key cancer cell signal transduction pathways as therapeutic targets. European Journal of Cancer, 42, 290\u2013294.","journal-title":"European Journal of Cancer"},{"key":"5619_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00117","volume":"8","author":"V Gouirand","year":"2018","unstructured":"Gouirand, V., Guillaumond, F., & Vasseur, S. (2018). Influence of the tumor microenvironment on cancer cells metabolic reprogramming. Frontiers in Oncology, 8, Article 117.","journal-title":"Frontiers in Oncology"},{"key":"5619_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154943","volume":"132","author":"MR Waarts","year":"2022","unstructured":"Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022). Targeting mutations in cancer. Journal of Clinical Investigation, 132, Article e154943.","journal-title":"Journal of Clinical Investigation"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05619-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05619-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05619-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:36:56Z","timestamp":1779331016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-026-05619-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5619"],"URL":"https:\/\/doi.org\/10.1007\/s12010-026-05619-8","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"4 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University and conducted in accordance with the principles outlined in the Declaration of Helsinki. All participants signed an informed consent form before the commencement of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}